Our mRNADisplay Technology
Our fully cell-free mRNA display platform enables screening of ultra-large libraries containing 10¹⁴–10¹⁵ unique variants, providing exceptional opportunities to identify rare binders with superior affinity and specificity.
mRNA display is one of the most powerful in vitro selection technologies, creating a stable covalent linkage between each translated protein and its encoding mRNA through a puromycin linker. This direct genotype-to-phenotype connection enables efficient recovery and amplification of high-affinity binders while supporting library sizes far beyond those achievable with cell-based display systems.
Ready-to-Go Display Libraries
Accelerate your antibody and DARPin discovery with Rx Biosciences' ready-to-screen, high-diversity display libraries. Our validated libraries eliminate the time and cost of library construction, enabling rapid identification of high-affinity binders for research, diagnostics, and therapeutic development.
Available Libraries
Human Naïve scFv Ribosome Display Library
(Complexity >1 × 10¹⁴)
DARPins Ribosome Display Library
(Complexity >1 × 10¹⁰)
10¹⁴–10¹⁵ Library Diversity
Screen ultra-large libraries to identify rare binders.
Cell-Free Selection
Completely in vitro discovery without transformation limits.
mRNA-Protein Linkage
Stable genotype-to-phenotype connection via puromycin.
High-Affinity Discovery
Rapid enrichment of superior affinity and specificity.
Advanced Engineering
Supports antibodies, peptides, mini-proteins, cyclic peptides, and non-natural amino acids.
10¹⁴–10¹⁵ Library Diversity
Screen ultra-large libraries to identify rare binders.
Cell-Free Selection
Completely in vitro discovery without transformation limits.
mRNA-Protein Linkage
Stable genotype-to-phenotype connection via puromycin.
High-Affinity Discovery
Rapid enrichment of superior affinity and specificity.
Advanced Engineering
Supports antibodies, peptides, mini-proteins, cyclic peptides, and non-natural amino acids.
Our Technology
Antibody LIbraries
Peptide Libraries
Mini-protein libraries
cDNA Libraries
Synthetic protein scaffold libraries
Libraries with non-natural amino acids & circular peptides
Antibody LIbraries
Peptide Libraries
Mini-protein libraries
cDNA Libraries
Synthetic protein scaffold libraries
Libraries with non-natural amino acids & circular peptides
OUR WORKFLOW
Library Design
In Vitro Transcription
mRNA-Puromycin Fusion
Cell-Free Translation
Target Binding
Selection & Washing
RNA Recovery
cDNA Amplification
Sequencing
Lead Candidate Identification
Library Design
In Vitro Transcription
mRNA-Puromycin Fusion
Cell-Free Translation
Target Binding
Selection & Washing
RNA Recovery
cDNA Amplification
Sequencing
Lead Candidate Identification
Iterative enrichment enables rapid identification of high-affinity binders from ultra-high-diversity libraries.
APPLICATIONS
- Therapeutic antibody discovery
- High-affinity peptide discovery
- Mini-protein engineering
- Protein scaffold development
- Affinity maturation
- Biomarker discovery
- Protein–protein interaction studies
- Diagnostic reagent development
- Target validation
SERVICE HIGHLIGHTS
- Ultra-high diversity libraries (>10¹⁴–10¹⁵ variants)
- Antibody libraries from immunized animals
- Peptide libraries of varying lengths
- Mini-protein discovery libraries
- cDNA libraries for mRNA display
- Libraries incorporating non-natural amino acids
- Cyclic peptide library construction and screening
- High-throughput selection and affinity maturation
- Validation by ELISA, Flow Cytometry (FACS), Surface Plasmon Resonance (Biacore), and other functional assays
WHY CHOOSE RX BIOSCIENCES?
- Custom library design and construction
- Ultra-large library generation
- Optimized cell-free transcription and translation
- Flexible screening strategies for challenging targets
- Sequence analysis and lead identification
- Comprehensive binding and functional characterization
- End-to-end support from library design to validated lead candidates
Accelerate Your Discovery Program
Rx Biosciences' mRNA display technology enables the rapid identification of high-affinity peptides, antibodies, mini-proteins, and engineered binders from some of the world's largest combinatorial libraries. Our integrated discovery platform delivers the speed, diversity, and precision needed to advance next-generation therapeutics, diagnostics, and research tools.